Indeed, the top 30 significantly enriched immune modulators in ME patients included CCL8, a ligand for the tumour infiltrating Treg cells chemokine receptor CCR8, PVR, a ligand for the T cell checkpoint protein TIGIT and ITGA8, which is known to activate TGFb (Fig. 5c). This evidence concerns the gene TGFB1 and neoplasm.